Neurocrine Biosciences (NBIX) Net Margin (2010 - 2026)

Neurocrine Biosciences' Net Margin history runs 16 years deep, the most recent figure standing at 24.3% for Q1 2026.

• Quarterly Net Margin rose 2292.0% year-over-year to 24.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.55% (up 888.0% YoY) and the FY2025 annual result came in at 16.73%, up 224.0% from the prior year.
• Net Margin was 24.3% for Q1 2026 at Neurocrine Biosciences, up from 19.08% in the prior quarter.
• Across five years, Net Margin topped out at 28.67% in Q4 2023 and bottomed at 84.5% in Q2 2022.
• A 5-year average of 8.88% and a median of 16.66% in 2023 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2022 — Net Margin slumped 9914 bps — and 2023, when it soared 10560 bps.
• Neurocrine Biosciences' Net Margin stood at 21.6% in 2022, then jumped by 33 bps to 28.67% in 2023, then tumbled by 43 bps to 16.43% in 2024, then increased by 16 bps to 19.08% in 2025, then advanced by 27 bps to 24.3% in 2026.
• Business Quant data shows NBIX's Net Margin at 24.3% in Q1 2026, 19.08% in Q4 2025, and 26.36% in Q3 2025.